Tu banner alternativo

Eseroline

Today, Eseroline is a highly relevant and topical topic that draws the attention of experts and the general public. It is a topic that does not leave anyone indifferent, since its repercussions can be very significant in different areas of society. For that reason, it is important to delve deeper into Eseroline to understand its impact and generate an informed debate about it. In this article, we will explore different aspects of Eseroline, from its origin and evolution to its possible implications in the future. In addition, we will analyze various perspectives on Eseroline with the aim of enriching knowledge and providing a more complete and global vision on this topic.

Tu banner alternativo

Eseroline
Skeletal formula
Ball-and-stick model
Clinical data
Other namesEseroline
ATC code
  • none
Identifiers
  • (3aR,8bS)-3,4,8b-trimethyl-2,3a-dihydro-1H-pyrroloindol-7-ol
CAS Number
PubChem CID
ChemSpider
UNII
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H18N2O
Molar mass218.300 g·mol−1
3D model (JSmol)
  • C12CCN(1N(C3=C2C=C(C=C3)O)C)C
  • InChI=1S/C13H18N2O/c1-13-6-7-14(2)12(13)15(3)11-5-4-9(16)8-10(11)13/h4-5,8,12,16H,6-7H2,1-3H3/t12-,13+/m1/s1
  • Key:HKGWQUVGHPDEBZ-OLZOCXBDSA-N
  (verify)

Eseroline is a drug which acts as an opioid agonist.[1] It is a metabolite of the acetylcholinesterase inhibitor physostigmine but unlike physostigmine, the acetylcholinesterase inhibition produced by eseroline is weak and easily reversible,[2][3] and it produces fairly potent analgesic effects mediated through the μ-opioid receptor.[4] This mixture of activities gives eseroline an unusual pharmacological profile,[5][6] although its uses are limited by side effects such as respiratory depression[7] and neurotoxicity.[8]

Synthesis

The alkylation of phenacetin (1) with dimethyl sulfate gives N-methylphenetidine (2). Treatment with 2-bromopropanoyl bromide gives 2-bromo-N-(4-ethoxyphenyl)-N-methylpropanamide (3). Treatment with aluminium trichloride results in 1,3-dimethyl-5-hydroxyoxindole (4). Alkylation with diethyl sulfate gives 5-ethoxy-1,3-dimethylindolin-2-one (5). Base-catalyzed treatment with chloroacetonitrile gives 2-(5-ethoxy-1,3-dimethyl-2-oxoindol-3-yl)acetonitrile (6). Catalytic hydrogenation of the nitrile group gives (7). Mono-methylation of the primary amine gives (8). Intramolecular reductive amination gives eserethole (9). Cleavage of the ethyl ether protecting group gave (-)-eseroline (10). Optional treatment with methyl isocyanide (MIC) leads to physostigmine.

Eseroline synthesis:[9][10][11]

References

  1. ^ Fürst S, Friedmann T, Bartolini A, Bartolini R, Aiello-Malmberg P, Galli A, et al. (September 1982). "Direct evidence that eseroline possesses morphine-like effects". European Journal of Pharmacology. 83 (3–4): 233–41. doi:10.1016/0014-2999(82)90256-4. PMID 6293841.
  2. ^ Jhamandas K, Elliott J, Sutak M (March 1981). "Opiatelike actions of eseroline, an eserine derivative". Canadian Journal of Physiology and Pharmacology. 59 (3): 307–10. doi:10.1139/y81-048. PMID 7194726.
  3. ^ Galli A, Renzi G, Grazzini E, Bartolini R, Aiello-Malmberg P, Bartolini A (April 1982). "Reversible inhibition of acetylcholinesterase by eseroline, an opioid agonist structurally related to physostigmine (eserine) and morphine". Biochemical Pharmacology. 31 (7): 1233–8. doi:10.1016/0006-2952(82)90009-0. PMID 7092918.
  4. ^ Agresti A, Buffoni F, Kaufman JJ, Petrongolo C (November 1980). "Structure--activity relationships of eseroline and morphine: ab initio quantum-chemical study of the electrostatic potential and of the interaction energy with water". Molecular Pharmacology. 18 (3): 461–7. PMID 7464812.
  5. ^ Galli A, Ranaudo E, Giannini L, Costagli C (November 1996). "Reversible inhibition of cholinesterases by opioids: possible pharmacological consequences". The Journal of Pharmacy and Pharmacology. 48 (11): 1164–8. doi:10.1111/j.2042-7158.1996.tb03914.x. PMID 8961166. S2CID 45395195.
  6. ^ Liu WF (April 1991). "Effect of eseroline on schedule-controlled behavior in the rat". Pharmacology, Biochemistry, and Behavior. 38 (4): 747–51. doi:10.1016/0091-3057(91)90236-U. PMID 1871191. S2CID 12857298.
  7. ^ Berkenbosch A, Rupreht J, DeGoede J, Olievier CN, Wolsink JG (February 1993). "Effects of eseroline on the ventilatory response to CO2". European Journal of Pharmacology. 232 (1): 21–8. doi:10.1016/0014-2999(93)90723-U. PMID 8458393.
  8. ^ Somani SM, Kutty RK, Krishna G (October 1990). "Eseroline, a metabolite of physostigmine, induces neuronal cell death". Toxicology and Applied Pharmacology. 106 (1): 28–37. Bibcode:1990ToxAP.106...28S. doi:10.1016/0041-008X(90)90102-Z. PMID 2251681.
  9. ^ Kulkarni MG, Dhondge AP, Borhade AS, Gaikwad DD, Chavhan SW, Shaikh YB, et al. (2009). "A novel and efficient total synthesis of (±)-physostigmine". Tetrahedron Letters. 50 (20): 2411–2413. doi:10.1016/j.tetlet.2009.03.012.
  10. ^ Harley-Mason J, Jackson AH (1954). "Hydroxytryptamines. Part II. A new synthesis of physostigmine". Journal of the Chemical Society (Resumed): 3651–3654. doi:10.1039/JR9540003651.
  11. ^ Wijberg JB, Speckamp WN (January 1978). "New total synthesis of dl-physostigmine (dl-eserine) via regioselective NaBH4-reduction of imides". Tetrahedron. 34 (15): 2399–2404. doi:10.1016/0040-4020(78)89058-9.
Wikious
Boobota
Sagapedia